Infasurf

Infasurf

calfactant

Manufacturer:

ONY Biotech

Distributor:

Pacific Healthcare
Concise Prescribing Info
Contents
Calfactant
Indications/Uses
Rescue treatment for premature infants who develop resp distress syndrome (RDS). Infants ≤72 hr w/ RDS & requiring endotracheal intubation. Prevention of RDS in premature infants at high risk for RDS. Prophylaxis at birth for premature infants <29 wk gestational age at significant risk for RDS.
Dosage/Direction for Use
Endotracheopulmonary 3 mL/kg every 12 hr for 3 doses. Prophylaxis at birth Premature infant <29 wk of gestational age at significant risk for RDS Administer w/in 30 min after birth.
Special Precautions
Interrupt administration & stabilize infant's condition before treatment resumption in the event of bradycardia, reflux into the endotracheal tube, airway obstruction, cyanosis, dislodgement of endotracheal tube or hyperventilation. Not a substitute for neonatal intensive care. Patients w/ both intraventricular hemorrhage & periventricular leukomalacia. Carefully monitor oxygenation & lung compliance for modification of O2 therapy & ventilatory support. Concomitant use w/ experimental therapies of RDS eg, high-frequency ventilation.
Adverse Reactions
Cyanosis, airway obstruction, bradycardia, surfactant reflux into the endotracheal tube, requirement for manual ventilation & reintubation.
MIMS Class
Other Drugs Acting on the Respiratory System
ATC Classification
R07AA02 - natural phospholipids ; Belongs to the class of lung surfactants. Used in the treatment of respiratory diseases.
Presentation/Packing
Form
Infasurf susp for endotracheopulmonary instillation 3 mL
Packing/Price
1's
Form
Infasurf susp for endotracheopulmonary instillation 6 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in